BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:zovaglutide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of zovaglutide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07443059-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:zovaglutide: Phase 1 readout est. (NCT07443059)
DESCRIPTION:zovaglutide\, phase 1\, Obesity.\nStudy: A Study of Zovaglutide
  (ZT002 Injection) in Participants With Impaired Kidney Function and Healt
 hy Participants\nEstimated primary completion: 3 December 2026. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/zovaglutide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07443059
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550816-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:zovaglutide: Phase 1 readout est. (NCT07550816)
DESCRIPTION:zovaglutide\, phase 1\, Obesity.\nStudy: Drug-drug Interaction 
 Study of ZT002 Injection in Overweight and Obese Participants\nEstimated p
 rimary completion: 5 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/zovaglutide#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07550816
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07697846-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20270113
DTEND;VALUE=DATE:20270114
SUMMARY:zovaglutide: Phase 1 readout est. (NCT07697846)
DESCRIPTION:zovaglutide\, phase 1\, Obesity.\nStudy: A Study to Investigate
  the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy A
 dults\nEstimated primary completion: 13 January 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/zovaglutide#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07697846
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07230119-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20270529
DTEND;VALUE=DATE:20270530
SUMMARY:zovaglutide: Phase 3 readout est. (NCT07230119)
DESCRIPTION:zovaglutide\, phase 3\, Obesity.\nStudy: A Study of Zovaglutide
  in Subjects With Overweight or Obesity (HORIZON-1)\nEstimated primary com
 pletion: 29 May 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /zovaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07230119
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07916194-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20270619
DTEND;VALUE=DATE:20270620
SUMMARY:zovaglutide: Phase 1 readout est. (NCT07916194)
DESCRIPTION:zovaglutide\, phase 1\, Obesity.\nStudy: A Study of Zovaglutide
  (ZT002 Injection) in Participants With Hepatic Impairment and Healthy Par
 ticipants\nEstimated primary completion: 19 June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/zovaglutide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07916194
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07812597-202@assetmemo.bio
DTSTAMP:20261121T010115Z
DTSTART;VALUE=DATE:20280113
DTEND;VALUE=DATE:20280114
SUMMARY:zovaglutide: Phase 2 readout est. (NCT07812597)
DESCRIPTION:zovaglutide\, phase 2\, Obesity.\nStudy: A Study Evaluating Saf
 ety and Tolerability of Switching From Semaglutide to Zovaglutide in Adult
 s With Obesity (HORIZON-SWITCH-SZ)\nEstimated primary completion: 13 Janua
 ry 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zovaglutide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0781
 2597
URL:https://assetmemo.bio/drug/zovaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
